Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study)

Exclusion Criteria

• •1. Patients who had NAs resistance;
• •2. Other antiviral, anti-neoplastic or immunomodulatory treatment;
• •3. Women with ongoing pregnancy or breast-feeding;
• •4. Co-infection with active hepatitis A, hepatitis C, hepatitis D(Those hospitals which have the ability to do the test will do) and/or human immunodeficiency virus (HIV);
• •5. ALT \>10 ULN;
• •6. LSM \>9kPa ;
• •7. History or other evidence of a medical condition associated with chronic liver disease other than viral hepatitis (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures, thalassemia);
• •8. Signs or symptoms of hepatocellular carcinoma;
• •9. Neutrophil count \< 1500 cells/mm3 or platelet count \<90,000 cells/mm3 at screening;
• •10. Hemoglobin \< 11.5 g/dL for females and \<12.5 g/dL for men;
• •11. Serum creatinine level \> 1.5 ULN in screening period.
• •12. Phosphorus \< 0.65 mmol/L;
• •13. ANA \> 1:100;
• •14. History of severe psychiatric disease;
• •15. History of a severe seizure disorder or current anticonvulsant use;
• •16. History of immunologically mediated disease, (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, rheumatoid arthritis etc.);
• •17. History of chronic pulmonary disease associated with functional limitation;
• •18. Diseases that IFN and Nucleotides or nucleosides are not suitable.